From time to time, investors encountered some of the best names in a specific industry, which are then subject to the best news and developments during the retention period. It seems the best choice today in the medical sector. Investors show a The main main strength This was noticed by the other main players in this industry Optimized higher capabilities.
Hims & her health today
Hims & Rels Health
As of 03:59 pm
- 52 weeks
- 11.20 dollars
▼
72.98 dollars
- P/E ratio.
- 75.14
- The target price
- $ 36.92
With a large gathering up to 25 % during the last trading week, shares shares HIMS & Her Health Inc. NYSE: HIMS It has become the center of attention to more purchase in the next months and four quarters. The last collapse in the price is attractive not only for the buyer of momentum, but also to appreciate investors, although the shares are already trading in what some may call the “expensive” assessments.
Given that the stock has not gathered from a random price, but rather from an important announcement that may change the future of the company, investors can start justifying higher assessments in stock prices and traditional complications compared to the rest of the peer group.
Here some Market aid factors remain optimistic about him.
Novo Nordisk collaborates a higher ceiling
In late April 2025, the leader of the Medical Industry, Novo Nordisk, announced that she had it Choose Hims and HERS as her latest partner To distribute the pioneering weight loss medicine, Wujofi. This decision not only indicates confidence in the HIMS & HERS business model, but is also a strong support for the broader upward status of the platform.
Previously, i.e. two The “gaps” in the company have been blamed GLP-1 products For weight management and weight loss, noting that the company lacks distribution channels and size to avoid complications below the line.
Now that this new cooperation has been declined, the market has been operated from non -believers in stocks. This increase in the two -number percentage has been removed from some of Open sellersWith the maximum pain of pain, forcing them to close their positions.
As of April 2025, Hims & Hers Stock has been reported to up to 33.3 % of her shares due in short positions, which is in no way high. However, a scenario calls for “Short pressure“Applicable in this case, including a tremendous closure of short positions, adds to the purchase pressure in the arrow step.
Why still Hims & HERS purchase
Some may think of the old saying Wall Street: If something is hitting newswire, then it is too late to enter the company or basic trade. In the case of Hims & HERS, this day does not apply. This belief can be justified by looking at some companies Basic drivers.
According to The latest quarterly offerHims & HERS shoots all cylinders today. When it comes to the column that collects everything together, inform users and HIMS & HERS 45 % joint growth Over the past 12 months, it clearly shows that the company is still in the stages of the growth boom.
Which – which User growthIt reaches 2.2 million, allowed Hims & her salary to generate up to $ 1.5 billion In revenue a Net growth rate of 69 % During the past year. The enormous growth topics in the company can be seen to start justifying some of the ups that were seen in today’s evaluations, especially since there are now new stimuli growth in the future.
It is not only growth for him. until 90 % of the company’s revenue includes subscriptionsCapital management and projections make a dream for valuable analysts and Wall Street analysts.
When talking about analysts, this is where investors can start measuring as the stock may go after that.
The market mocks the stocks
HIMS & HERS Health Stock Expectations today
$ 36.92
Hold
Based on 13 analyst classifications
| The current price | $ 33.06 |
|---|---|
| High expectations | $ 68.00 |
| Average expectations | $ 36.92 |
| Low expectations | 23.00 dollars |
HIMS & HERS Health Desicite Defelds
Because Hims & her salary now Trading 38 % of its highest level 52 weeks, Investors will notice a relatively decrease The target consensus price From $ 36.9 per share, only appears 5.2 % implicit upside down In terms of shares trading today.
Analysts rarely look Enhancing or going to climb on stocks That was low in performance or in the Habboudia area.
However, when investors examine profits expectations for the share (EPS), especially the $ 0.16 projection for Q3 2025, it reflects a significant increase of 77 % from $ 0.09 currently. When EPS goes, as well as the price of the arrow, this is the viewpoint of the analyst that cannot be affected by price movement and one can rely on it today.
Perhaps this is why the markets are now ready to pay up to 79.7X in price to profits (P/E) Attributes, severe premium for the rest of the 22.4X rating in the medical sector. As experienced investors know, the markets are always a good reason for Pay excess amounts to some sharesHims & her bullish factors show enough to justify installment.
Before you think about his health and health, you will want to hear this.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has selected the five shares whom the top analysts quietly whispered to their customers to buy now before wiping the broader market … Hims & HERS Health was not in the list.
While Hims & HERS Health currently has a suspended classification between analysts, higher -rated analysts believe that these five stocks buy better.
Show the five stocks here
Enter your email address and we will send you the Marketbeat menu that includes seven shares and why their long -term expectations are very promising.
